Products & Services · Total revenues
Regeneron Technology Transfer Obligation — Total revenues
Year-over-year, this metric declined by 100.0%, from $2.43M to $0.
Analysis
Metric ID:
alny_segment_regeneron_technology_transfer_obligation_total_revenuesHistorical Data
13 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.43M | $0 | $0 | $0 | $0 |
| QoQ Change | — | — | — | — | — | — | — | — | — | -100.0% | — | — | — |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | -100.0% |
Range$0 – $2.43M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's regeneron technology transfer obligation — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported regeneron technology transfer obligation — total revenues of $0 in Q1 2026.
- How has Alnylam Pharmaceuticals's regeneron technology transfer obligation — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's regeneron technology transfer obligation — total revenues decreased by 100.0% year-over-year, from $2.43M to $0.